SCT for BT
| Factor . | SCT (n = 37) . | Allo-SCT (n = 23) . | Auto-SCT (n = 14) . |
|---|---|---|---|
| Median age, y (range) | 36.3 (17.1-57.2) | 31.3 (17.1-50.5) | 45.8 (31-57.2) |
| Source of stem cells | |||
| BM | 20 | 19 | 1 |
| PBSC | 17 | 4 | 13 |
| Disease status at time of SCT | |||
| 2nd CP | 7 | 6 | 1 |
| ≥ 3rd CP | 6 | 5 | 1 |
| Refractory | 13 | 7 | 6 |
| Untreated | 7 | 2 | 5 |
| Relapsed | 4 | 3 | 1 |
| Median TNC, × 108/kg (range) | 3.8 (0.3-11) | 3.2 (0.3-11) | 5.0 (1.5-11) |
| Response to SCT (%) | |||
| Chronic phase | 20 (54) | 16 (69) | 4 (28) |
| Refractory | 12 (32) | 4 (17) | 8 (57) |
| Not evaluable | 5 (13) | 3 (13) | 2 (14) |
| Median survival after BT, mo (95% CI) | 11.0 (7.7-14) | 11.6 (10.7-12.5) | 5.8 (3.5-8.0) |
| Factor . | SCT (n = 37) . | Allo-SCT (n = 23) . | Auto-SCT (n = 14) . |
|---|---|---|---|
| Median age, y (range) | 36.3 (17.1-57.2) | 31.3 (17.1-50.5) | 45.8 (31-57.2) |
| Source of stem cells | |||
| BM | 20 | 19 | 1 |
| PBSC | 17 | 4 | 13 |
| Disease status at time of SCT | |||
| 2nd CP | 7 | 6 | 1 |
| ≥ 3rd CP | 6 | 5 | 1 |
| Refractory | 13 | 7 | 6 |
| Untreated | 7 | 2 | 5 |
| Relapsed | 4 | 3 | 1 |
| Median TNC, × 108/kg (range) | 3.8 (0.3-11) | 3.2 (0.3-11) | 5.0 (1.5-11) |
| Response to SCT (%) | |||
| Chronic phase | 20 (54) | 16 (69) | 4 (28) |
| Refractory | 12 (32) | 4 (17) | 8 (57) |
| Not evaluable | 5 (13) | 3 (13) | 2 (14) |
| Median survival after BT, mo (95% CI) | 11.0 (7.7-14) | 11.6 (10.7-12.5) | 5.8 (3.5-8.0) |
PBSC indicates peripheral blood stem cell; CP, chronic phase.